Corpus Intelligence IC Memo — JORDAN VALLEY MEDICAL CENTER 2026-04-26 06:55 UTC
IC Memo — JORDAN VALLEY MEDICAL CENTER
Investment Committee Memorandum | UT | 267 beds | Grade C | EBITDA uplift $20.2M
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

JORDAN VALLEY MEDICAL CENTER

CCN 460051 | SALT LAKE, UT | 267 beds | April 26, 2026
EBITDA BridgeData Room
C
Investability

1. Target Overview & Investment Thesis

JORDAN VALLEY MEDICAL CENTER is a 267-bed suburban community hospital in SALT LAKE, UT with $274.2M in net patient revenue and a 17.2% operating margin. The hospital serves a payer mix of 12.1% Medicare, 12.3% Medicaid, and 75.6% commercial.

Thesis: Platform Growth. Our ML models identify $20.2M in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from 17.2% to 24.5% (+736bps).

Net Revenue HCRIS$274.2M
Current EBITDA COMPUTED$47.1M
Operating Margin COMPUTED17.2%
Occupancy HCRIS34.5%
Revenue / Bed COMPUTED$1.0M
Net-to-Gross HCRIS33.2%
Distress Probability ML54.3%

2. Market Context & Competitive Position

59
UT Hospitals
8.0%
State Median Margin
10
Comparable Hospitals

UT has 59 Medicare-certified hospitals with a median operating margin of 8.0%. The target's margin of 17.2% places it above the state median. Among 10 size-comparable peers (134-534 beds), the median margin is 12.0%. The target performs in line with or above peers.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (134-534), prioritizing same-state peers. 10 hospitals in the comp set.

HospitalStateBedsRevenueMargin
JORDAN VALLEY MEDICAL CENTER (Target)UT267$274.2M17.2%
INTERMOUNTAIN MEDICAL CENTERUT486$1.24B8.9%
PRIMARY CHILDRENS HOSPITALUT287$895.5M5.6%
ST GEORGE REGIONAL HOSPITALUT256$790.1M12.0%
UTAH VALLEY HOSPITALUT338$707.3M7.6%
MCKAY-DEE HOSPITALUT236$629.9M12.6%
ST MARKS HOSPITALUT263$539.0M44.0%
LDS HOSPITALUT216$307.0M-5.5%
OGDEN REGIONAL MEDICAL CENTERUT174$299.3M47.4%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $20.2M (736bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$5.8M+210bp18mo
Cost to Collect4.5%2.5%$5.5M+200bp12mo
Denial Rate Reduction12.0%6.5%$5.4M+198bp12mo
A/R Days Reduction5200.0%3800.0%$3.3M+122bp9mo
Clean Claim Rate88.0%96.0%$175K+6bp6mo

5. EBITDA Bridge

Net Collection Rate
$5.8M
Cost to Collect
$5.5M
Denial Rate Reduction
$5.4M
A/R Days Reduction
$3.3M
Clean Claim Rate
$175K
Total EBITDA Uplift$20.2M
Current EBITDA$47.1M
+ RCM Uplift+$20.2M
Pro Forma EBITDA$67.3M
Current Margin17.2%
Pro Forma Margin24.5%
WC Released (1x)$10.5M

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$72.4M$512.3M7.07x47.9%
Base (11x exit)10.0x11.0x$72.4M$587.0M8.11x52.0%
Bull Case9.0x11.0x$65.2M$677.2M10.39x59.7%
Bull (12x exit)9.0x12.0x$65.2M$758.0M11.63x63.3%
Bear Case11.0x10.0x$79.7M$387.9M4.87x37.2%
Bear (11x exit)11.0x11.0x$79.7M$452.5M5.68x41.5%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
MediumLow occupancyAt 34.5%, fixed costs are spread over fewer patient days. Mitigant: volume growth is an additional upside lever not modeled in base case
HighElevated distress probabilityModel estimates 54.3% probability of financial distress. Mitigant: distressed entry pricing (7-9x) compensates for risk

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 10 hospitals with 134-534 beds
  • Same-state prioritization (n=11)
  • Comp margins: P25=7.6% / P50=12.0% / P75=29.1%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.